BRCA2 and prostate cancer: For example, in prostate cancer, PCAT-1 was proved to have a prominent inhibitory effect on the HR activity by a direct interaction with the 3′UTR of BRCA2, thus affecting subsequent post-transcriptional suppression of BRCA2 (Prensner et al., 2014).